Alnylam Pharmaceuticals | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Arrowhead Research USD 1.01B 126.11M 2024-12
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Incyte USD 5.75B 305.04M 2025-03
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
Moderna USD 12.7B 1.44B 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
PTC Therapeutics USD 1.71B 137.21M 2024-12
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Sanofi 132.8B 3.04B 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Takeda JPY 15.11T 533.85B 2024-12
Tectonic Therapeutic USD 152.9M 15.81M 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12
Xencor USD 951.94M 31.69M 2024-12



Alnylam Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.